Draft:HrC Cancer Blood Test

The HrC cancer Blood Test is a new method to provide early cancer prognosis and diagnosis.

Description
Considered as path-breaking, the new blood test is designed to pick up specific markers to show changes of how stem cells are behaving. After the trial of 1000 patients, it was published Stem Cell Reviews and the science behind it was also outlined in journal Stem Cells. The test can detect the absence of cancer or its presence. It can detect about 25 types of cancer including breast, liver, ovarian, lung, leukemia, renal, bladder, prostate, pancreatic, cervical and colon.

The test identifies cancer, a year before tumours are formed. It is a blood biopsy technique that shows changes in the stem cells behaviour. It could be a biggest breakthrough in cancer detection.

The test uses VSEL/CSC specific bio-markers in peripheral blood. VSELs are very small embryonic-like stem cells which circulate in the blood. These stem cells led to the development of the test.

Development
It is co-developed by Mumbai-based biotech firm Epigeneres and Singapore-based diagnostic company Tzar Labs in 2023. Vinay Kumar Tripathi and family members hold majority stake in the two companies, Tzar Labs and Epigeneres Biotechnology private limited.

The Mumbai-based company raised $6 Mn in a Series B funding round. The test is expected to cost less than Rs.10,000. Patents were filed by Tzar Labs in India, apart from US, Europe, Japan, Singapore and China. The test is being introduced in UK by a Doncaster-based business headed by co-founder Steve Smith. He also conducting a study in UK.